atai Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference
01 Mars 2023 - 10:01PM
atai Life Sciences to Participate in the Cowen 43rd Annual Health
Care Conference
atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage
biopharmaceutical company aiming to transform the treatment of
mental health disorders, will participate in the Cowen 43rd Annual
Health Care Conference.
Details of the company’s panel participation are as follows:
Cowen 43rd Annual Health Care
Conference
Format: Neuropsych Corporate
Panel
Date and Time: Monday, March 6th,
12:50 p.m. – 1:20 p.m. ET
Location: Boston, MA
A live webcast of the panel will be available on atai’s website
under Events on the Investors section of the atai website:
https://ir.atai.life/news-events/events/. An archived replay of the
webcast will be available for up to 30 days following the panel
discussion.
About atai Life Sciences
atai Life Sciences is a clinical-stage biopharmaceutical company
aiming to transform the treatment of mental health disorders.
Founded in 2018 as a response to the significant unmet need and
lack of innovation in the mental health treatment landscape, atai
is dedicated to acquiring, incubating, and efficiently developing
innovative therapeutics to treat depression, anxiety, addiction,
and other mental health disorders.
By pooling resources and best practices, atai aims to
responsibly accelerate the development of new medicines across its
companies to achieve clinically meaningful and sustained behavioral
change in mental health patients.
atai's vision is to heal mental health disorders so that
everyone, everywhere can live a more fulfilled life. For more
information, please visit www.atai.life.
Contact Information
Investor Contact:Stephen BardinChief Financial
OfficerIR@atai.life
Media Contact:Allan MalievskySenior Director, External
AffairsPR@atai.life
ATAI Life Sciences NV (TG:9VC)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
ATAI Life Sciences NV (TG:9VC)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024